Christopher E. Dandoy, MD, MSc, a professor at Cincinnati Children’s Hospital, shares advice for how to overcome the challenges in managing transplanted-associated thrombotic microangiopathy (TA-TMA). The primary challenges are diagnosing and identifying TA-TMA in patients.

Dandoy recommends screening for TA-TMA to overcome this issue. Institutions should obtain complete blood counts for the first month in patients following transplant, as well as renal profiles to look at kidney injury on a daily basis. In addition, physicians should look at lactate dehydrogenase, urine, and for signs of schistocytes in the blood. Dandoy concludes they should also monitor blood pressure closely.

Videos

Christopher E. Dandoy, MD, MSc, shares advice for how to overcome the challenges in managing transplanted-associated thrombotic microangiopathy. The primary challenges are diagnosing and identifying TA-TMA in patients.

Dr. Dandoy on Overcoming Challenges with TA-TMA

Christopher E. Dandoy, MD, MSc, assistant professor of pediatrics at Cincinnati Children’s Hospital, says that patients undergoing allogeneic stem cell transplant are at high-risk of developing thrombotic microangiopathy (TMA).

TMA occurs in 30% of these patients and can occur as early as 7 days after transplant. When it is identified to be present, the patient can be properly treated right away, Dandoy notes.

Tools from these data presented at the 2019 Transplantation & Cellular Therapy Meetings as well as tools from other data can be used to identify these patients even earlier.

2019 Transplantation and Cellular Therapy Meetings

Christopher E. Dandoy, MD, MSc, says that patients undergoing allogenic stem cell transplant are at high-risk of developing thrombotic microangiopathy.

Christopher E. Dandoy, MD, MSc

Articles

Dr. Dandoy on Overcoming Challenges with TA-TMA

Dr. Dandoy on TMA Risk After Pediatric Allogeneic Stem Cell Transplant